Xenon Pharmaceuticals (XENE) EBITDA (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of EBITDA data on file, last reported at -$112.3 million in Q1 2026.

• On a quarterly basis, EBITDA fell 54.43% year-over-year to -$112.3 million in Q1 2026; TTM through Mar 2026 was -$412.7 million, a 40.84% decrease from a year earlier, with the FY2025 full-year figure at -$373.1 million, down 33.57% from the prior year.
• EBITDA for Q1 2026 stood at -$112.3 million, down from -$109.8 million in the prior quarter.
• Over the last five years, EBITDA for XENE reached as high as -$17.4 million in Q1 2022 and fell as low as -$112.3 million in Q1 2026.
• Historically, EBITDA has averaged -$65.2 million across 5 years, with a median of -$59.0 million in 2024.
• Across the five-year window, EBITDA slipped 8.16% in 2022 and plunged 182.41% in 2023, its largest moves.
• Year by year, EBITDA stood at -$43.3 million in 2022, then dropped by 23.92% to -$53.7 million in 2023, then tumbled by 44.29% to -$77.5 million in 2024, then tumbled by 41.68% to -$109.8 million in 2025, then retreated by 2.33% to -$112.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$112.3 million in Q1 2026, -$109.8 million in Q4 2025, and -$96.3 million in Q3 2025.